Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Cisplatin-resistant human ovarian carcinoma cells stained with Toluidine blue and observed with<br />
a Zeiss axiophot light microscope in a phase contrast mode.<br />
Expected results<br />
The project provides the integration of diff erent scientifi c<br />
areas that are culturally well separated into more established<br />
medical approaches to impact health determinant in ovarian<br />
cancer disease.<br />
It supports the discovery of new potential anticancer drugs<br />
with non-cross resistance profi les; the new potential drug<br />
candidate will be ready to enter the pharmacological phase.<br />
If the new identifi ed molecules will be moderately/very<br />
active with good bioavailability in vitro against ovarian cancer,<br />
these products will be very interesting to larger pharmacompany<br />
and could provide a successful technological transfer<br />
outcome.<br />
The proposed research could provide the technical developments<br />
and innovation, which could have a large impact on<br />
Biotech industry. The selection of the participating SME<br />
partners guarantees that the new knowledge (methods,<br />
potential drug(s) candidate(s)) might be transformed into<br />
new technology and new products.<br />
Potential applications<br />
The proposed research can lead to technical developments<br />
and innovation, which could have a large impact on the biotech<br />
industry. The selection of the participating SME partners<br />
guarantees that the new knowledge – methods and potential<br />
drug(s) candidate(s) – will be transformed into new<br />
technology and new products. The Consortium, in addition<br />
to its contribution to the project’s basic research by providing<br />
a suitable discovery chemistry programme, will be<br />
responsible for further development of the selected promising<br />
new chemical entities, comprising intellectual property<br />
protection, and chemical and pharmaceutical development.<br />
214<br />
Coordinator<br />
Maria Paola Costi<br />
University of Modena<br />
and Reggio Emilia<br />
Modena, Italy<br />
costimp@unimore.it<br />
Partners<br />
Rebecca Wade<br />
EML <strong>Research</strong> gGmbH<br />
Heidelberg, Germany<br />
Paolo Lombardi<br />
Naxospharma srl<br />
Cesate (MI), Italy<br />
Hannu Myllykallio<br />
Institut de Génétique et Microbiologie<br />
Université Paris-Sud<br />
Orsay, France<br />
Massimo Baroni<br />
Molecular Discovery<br />
Ponte San Giovanni (PG), Italy<br />
Robert Stroud<br />
UCSF-Genentech Hall, UCSF<br />
San Francisco, USA<br />
Project number<br />
LSHC-CT-2006-037852<br />
EC contribution<br />
€ 1 902 150<br />
Duration<br />
36 months<br />
Starting date<br />
01/10/2006<br />
Instrument<br />
STREP – SME<br />
Project website<br />
www.lights-EU.org<br />
CANCER RESEARCH PROJECTS FUNDED UNDER THE SIXTH FRAMEWORK PROGRAMME
Change language